vimarsana.com
Home
Live Updates
RELYVRIO® and AMX0114 Data to be Presented at 34th Inte
RELYVRIO® and AMX0114 Data to be Presented at 34th Inte
RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
Amylyx Pharmaceuticals, Inc. today announced that several abstracts detailing data on AMX0035 and the Company’s investigational antisense oligonucleotide, AMX0114, for the potential treatment of...
Related Keywords
Massachusetts ,
United States ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Phoenix ,
Arizona ,
Canada ,
Seanm Healey ,
,
Amylyx Pharmaceuticals ,
Nasdaq ,
Access Program ,
Twitter ,
Exchange Commission ,
Leandrop Rizzuto Foundation ,
International Symposium ,
Company Phase ,
Linkedin ,
Amylyx Pharmaceuticals Inc ,
United States Expanded Access Program ,
Joint Model ,
Assessing Mortality Adjusted Progression ,
Amyotrophic Lateral Sclerosis ,
Clinical Trials ,
Sodium Phenylbutyrate ,
Rating Scale ,
Planned Studies ,
Further Elucidate ,
Composite Diagnostic Biomarker ,
Experimental Approach ,
Real World Experience ,
Combination Sodium Phenylbutyrate ,
Preliminary Experience With Sodium Phenylbutyrate ,
Critical Effector ,
Axonal Degeneration ,
Safety Information ,
Enterohepatic Circulation Disorders ,
Pancreatic Disorders ,
Patients Sensitive ,
High Sodium ,
Rating Scale Revised ,
New England Journal ,
Bucket Challenge ,
Private Securities Litigation Reform Act ,
Amylyx United States Securities ,
Amylyx Quarterly Report ,
Markets ,